ClinicalTrials.gg
Not yet recruitingNCT07940036INSIGHT-RCTUpdated Nov 16, 2026

Skin Cancer Detection in Primary Care With and Without DermaSensor

An interventional study of DermaSensor in Skin Cancer, Basal Cell Cancer and Squamous Cell Carcinoma, sponsored by DermaSensor, Inc.. Not yet recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionMelanomaRegistry: Skin NeoplasmsReclassifiedWhy we changed it
Registry
Skin Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Melanoma
Why
  1. The study's listed conditions name Melanoma, a narrower term within Skin Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by DermaSensor, Inc. · Not applicable, Interventional, and Health services research

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 2,049 studies in Melanoma with a site in United States — 243 open to participants now, 440 under way, 32 of them phase 3. Melanoma · United States.

Planned enrollment
226th of 1,749
200 · median 37
Started
2026
with 50 others
No phase
159 of 2,049
31 open now
Primary completion
2028-06
later than 318 of 435 live
Registered
2,048th of 2,049
by date

Among the 2,049 studies in Melanoma with a site in United States, this one is the 226th largest by planned enrollment of the 1,749 interventional ones that give a count, is one of 51 that started in 2026, is one of 159 with no phase, reaches primary completion later than 318 of the 435 other live ones, and was the 2,048th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

243 of the 2,049 studies in Melanoma with a site in United States are open now. Recruiting first, the newest first:

238 more — sign in →

All 243 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,049 studies in Melanoma with a site in United States, or all of them as a file.
02

Study summary

This randomized controlled trial evaluates whether primary care physician access to the DermaSensor device increases the proportion of patients with histopathology-confirmed skin cancer compared with physician standard clinical assessment alone. Participating physicians are randomized and outcomes are drawn from existing electronic health record data for up to 500,000 patient encounters.

03

Conditions studied

  • Skin Cancer
  • Basal Cell Cancer
  • Squamous Cell Carcinoma
  • Melanoma (Skin Cancer)
  • Melanoma In Situ
  • Melanoma Detection
  • Melanoma

Browse trials for

Keywords

  • medical device
  • skin cancer detection
  • elastic scattering spectroscopy
  • spectroscopy
  • Artificial Intelligence (AI)
  • detection
04

In context

Melanoma Reclassified

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

This study's planned enrollment of 200 is above the median of 40 across 2,650 interventional studies indexed under Melanoma.

Browse Melanoma studies →

Lead sponsor

DermaSensor, Inc. is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Melanoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Skin Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Practicing primary care provider in the labeled user population for the DermaSensor device (per the Instructions for Use)
  • Practicing at a participating site that uses an EMR system modifiable at the user level
  • Practicing at a participating site that routinely documents skin check data, including coding for skin checks and lesion diagnoses
  • Practicing at a participating site where pathology results for patients referred to dermatology are routinely accessible for study analyses

Exclusion criteria

Exclusion Criteria:

- Not actively practicing in primary care at a participating study site

06

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • No intervention
    Unaided standard care

    Primary care clinics continuing routine assessment of skin lesions without access to the DermaSensor device.

  • Experimental
    DermaSensor-aided care

    Primary care clinics with access to the DermaSensor device as an adjunct to clinical assessment of skin lesions.

    Device: DermaSensor

Interventions

  • DeviceDermaSensor

    Handheld device used by primary care physicians as an adjunct to clinical assessment of skin lesions suggestive of skin cancer, per its labeling.

07

What researchers measure

Primary outcomes

  1. Proportion of patients with histopathology-confirmed skin cancer

    Proportion of all patients seen by participating primary care physicians with a skin cancer (melanoma, basal cell carcinoma, or squamous cell carcinoma) confirmed by histopathology within 12 months of the initial visit, compared between device-aided and unaided physicians.

    Time frame: Within 12 months of the initial primary care visit

Secondary outcomes

  1. Number needed to refer or biopsy (NNRB)

    Proportion of biopsies returning a malignant result and proportion of dermatology referrals returning a malignant result, compared between device-aided and unaided physicians.

    Time frame: Within 12 months of the initial primary care visit

  2. Skin cancers identified after a Monitor result or non-referral decision

    Skin cancers confirmed during follow-up after an initial device Monitor result or a non-referral/non-biopsy decision, with stage and severity characterized, compared between groups.

    Time frame: Within 12 months of the initial primary care visit

  3. Change in skin cancer detection rate among device physicians

    Rate of change in skin cancer detection among physicians using the device, compared with the same physicians before device access, the unaided arm, and non-user physicians in the device arm.

    Time frame: From pre-device baseline period through study completion

  4. Time to biopsy or dermatologist evaluation and to treatment

    Interval from initial primary care presentation to (1) biopsy or dermatologist evaluation and (2) treatment of the skin lesion, compared between groups.

    Time frame: Within 12 months of the initial primary care visit

08

Study locations

1 site
  • SSM Health
    St Louis, Missouri 63131, United States
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jun 2028, 19 months later.

Of 227 interventional studies with no phase under Melanoma, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 19 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 2, 2026
First posted
Nov 16, 2026
StartEst.
Nov 10, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2028
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07940036
Lead sponsor
DermaSensor, Inc.
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Jun 2028 (estimated)
Completion
Jun 2028 (estimated)
Last update
Nov 16, 2026

Study contacts

Justin Frazier, MS
Contact
justin.frazier@dermasensor.com
508-776-0044

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion